0.66
-0.0107(-1.61%)
Currency In USD
| Previous Close | 0.67 |
| Open | 0.66 |
| Day High | 0.69 |
| Day Low | 0.65 |
| 52-Week High | 1.7 |
| 52-Week Low | 0.62 |
| Volume | 219,901 |
| Average Volume | 620,909 |
| Market Cap | 34.43M |
| PE | -1.08 |
| EPS | -0.61 |
| Moving Average 50 Days | 0.72 |
| Moving Average 200 Days | 0.74 |
| Change | -0.01 |
If you invested $1000 in Xilio Therapeutics, Inc. (XLO) since IPO date, it would be worth $40.99 as of January 14, 2026 at a share price of $0.656. Whereas If you bought $1000 worth of Xilio Therapeutics, Inc. (XLO) shares 3 years ago, it would be worth $240.84 as of January 14, 2026 at a share price of $0.656.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
GlobeNewswire Inc.
Jan 08, 2026 1:30 PM GMT
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved develo
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Nov 07, 2025 2:05 PM GMT
40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Co
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Nov 07, 2025 2:01 PM GMT
Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindode